A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

• Intraocular pressure[ Time Frame: Week 1, Month 3 ]
  Decrease in mean diurnal IOP reduction

This is a Phase III, randomized, double-masked, active-controlled, parallel-group, multi-center study. Subjects diagnosed with glaucoma or OHT who meet eligibility criteria at Visit 1 (Screening) will washout of their current topical IOP-lowering medication(s), if any. After completing the required washout period, subjects will return for Visit 2 (Baseline, Day 1). Subjects who meet all eligibility criteria at baseline will be randomized to receive double-masked treatment for 3 months. Approximately 400 adult subjects and up to 30 pediatric subjects with glaucoma or OHT who meet all eligibility criteria will be randomized in a 1:1 ratio to receive either: - DE-117 Ophthalmic Solution once daily and Vehicle once daily, or - Timolol Maleate Ophthalmic Solution 0.5% twice daily. The study will evaluate the efficacy and safety of DE-117 Ophthalmic Solution compared with Timolol Maleate Ophthalmic Solution 0.5% in subjects with glaucoma or OHT through Month 3.

• Drug: DE-117 Ophthalmic Solution
  Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
• Drug: Timolol Maleate Ophthalmic Solution 0.5%
  Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily and Vehicle once daily for 3 months

• Experimental: DE-117 Ophthalmic Solution
  Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
• Active Comparator: Timolol Maleate Ophthalmic Solution 0.5%
  Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily and Vehicle once daily for 3 months